# A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

> **NCT06555068** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 528 (estimated)

## Conditions studied

- Advanced Unresectable or Metastatic Breast Cancer

## Interventions

- **DRUG:** HRS-6209 in Combination with Fulvestrant
- **DRUG:** HRS-6209 in Combination with HRS-1358
- **DRUG:** HRS-6209 in Combination with Letrozole
- **DRUG:** HRS-6209 in Combination with HRS-8080
- **DRUG:** HRS-6209 in Combination with HRS-1358

## Key facts

- **NCT ID:** NCT06555068
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-08
- **Target enrollment:** 528 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06555068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06555068, "A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06555068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*